[1]
|
Bowie, A.G. and Unterholzner, L. (2008) Viral Evasion and Subversion of Pattern-Recognition Receptor Signalling. Nature Reviews Immunology, 8, 911-922. https://doi.org/10.1038/nri2436
|
[2]
|
Fitzgerald, K.A., McWhirter, S.M., Faia, K.L., Rowe, D.C., Latz, E., Golenbock, D.T., et al. (2003) IKKε and TBK1 Are Essential Components of the IRF3 Signaling Pathway. Nature Immunology, 4, 491-496.
https://doi.org/10.1038/ni921
|
[3]
|
Abe, T., Barber, G.N. and Williams, B. (2014) Cytosolic-DNA-Mediated, STING-Dependent Proinflammatory Gene Induction Necessitates Canonical NF-κB Activation through TBK1. Journal of Virology, 88, 5328-5341.
https://doi.org/10.1128/JVI.00037-14
|
[4]
|
Hammaker, D., Boyle, D.L. and Firestein, G.S. (2012) Synoviocyte Innate Immune Responses: TANK-Binding Kinase-1 as a Potential Therapeutic Target in Rheumatoid Arthritis. Rheumatology, 51, 610-618.
https://doi.org/10.1093/rheumatology/ker154
|
[5]
|
Chau, T.-L., Gioia, R., Gatot, J.-S., Patrascu, F., Carpentier, I., Chapelle, J.-P., et al. (2008) Are the IKKs and IKK-Related Kinases TBK1 and IKK-ɛ Similarly Activated? Trends in Biochemical Sciences, 33, 171-180.
https://doi.org/10.1016/j.tibs.2008.01.002
|
[6]
|
Wild, P., Farhan, H., McEwan, D.G., Wagner, S., Rogov, V.V., Brady, N.R., et al. (2011) Phosphorylation of the Autophagy Receptor Optineurin Restricts Salmonella Growth. Science, 333, 228-233.
https://doi.org/10.1126/science.1205405
|
[7]
|
Hasan, M. and Yan, N. (2016) Therapeutic Potential of Targeting TBK1 in Autoimmune Diseases and Interferonopathies. Pharmacological Research, 111, 336-342. https://doi.org/10.1016/j.phrs.2016.04.008
|
[8]
|
Reilly, S.M., Chiang, S.-H., Decker, S.J., Chang, L., Uhm, M., Larsen, M.J., et al. (2013) An Inhibitor of the Protein Kinases TBK1 and IKK-ɛ Improves Obesity-Related Metabolic Dysfunctions in Mice. Nature Medicine, 19, 313-321.
https://doi.org/10.1038/nm.3082
|
[9]
|
Oral, E.A., Reilly, S.M., Gomez, A.V., Meral, R., Butz, L., Ajluni, N., et al. (2017) Inhibition of IKKɛ, and TBK1 Improves Glucose Control in a Subset of Patients with Type 2 Diabetes. Cell Metabolism, 26, 157-70.e7.
https://doi.org/10.1016/j.cmet.2017.06.006
|
[10]
|
Xiao, Y., Zou, Q., Xie, X., Liu, T., Li, H.S., Jie, Z., et al. (2017) The Kinase TBK1 Functions in Dendritic Cells to Regulate T Cell Homeostasis, Autoimmunity, and Antitumor Immunity. Journal of Experimental Medicine, 214, 1493-1507. https://doi.org/10.1084/jem.20161524
|
[11]
|
Barbie, D.A., Tamayo, P., Boehm, J.S., Kim, S.Y., Moody, S.E., Dunn, I.F., et al. (2009) Systematic RNA Interference Reveals That Oncogenic KRAS-Driven Cancers Require TBK1. Nature, 462, 108-112.
https://doi.org/10.1038/nature08460
|
[12]
|
Oakes, J.A., Davies, M.C. and Collins, M.O. (2017) TBK1: A New Player in ALS Linking Autophagy and Neuroinflammation. Molecular Brain, 10, Article No. 5. https://doi.org/10.1186/s13041-017-0287-x
|
[13]
|
Tu, D., Zhu, Z., Zhou, A.Y., Yun, C.-H., Lee, K.-E., Toms Angela, V., et al. (2013) Structure and Ubiquitination-Dependent Activation of TANK-Binding Kinase 1. Cell Reports, 3, 747-758.
https://doi.org/10.1016/j.celrep.2013.01.033
|
[14]
|
Larabi, A., Devos, J.M., Ng, S.-L., Nanao, M.H., Round, A., Maniatis, T., et al. (2013) Crystal Structure and Mechanism of Activation of TANK-Binding Kinase 1. Cell Reports, 3, 734-746. https://doi.org/10.1016/j.celrep.2013.01.034
|
[15]
|
Ma, X., Helgason, E., Phung, Q.T., Quan, C.L., Iyer, R.S., Lee, M.W., et al. (2012) Molecular Basis of Tank-Binding Kinase 1 Activation by Transautophosphorylation. Proceedings of the National Academy of Sciences, 109, 9378.
https://doi.org/10.1073/pnas.1121552109
|
[16]
|
Zhao, B., Du, F., Xu, P., Shu, C., Sankaran, B., Bell, S.L., et al. (2019) A Conserved PLPLRT/SD Motif of STING Mediates the Recruitment and Activation of TBK1. Nature, 569, 718-722. https://doi.org/10.1038/s41586-019-1228-x
|
[17]
|
Li, J., Li, J., Miyahira, A., Sun, J., Liu, Y., Cheng, G., et al. (2012) Crystal Structure of the Ubiquitin-Like Domain of Human TBK1. Protein & Cell, 3, 383-391. https://doi.org/10.1007/s13238-012-2929-1
|
[18]
|
Zhao, C. and Zhao, W. (2019) TANK-Binding Kinase 1 as a Novel Therapeutic Target for Viral Diseases. Expert Opinion on Therapeutic Targets, 23, 437-446. https://doi.org/10.1080/14728222.2019.1601702
|
[19]
|
Zhang, T., Qian, Y., Wang, S., Huang, G., Zhang, L. and Xue, Z. (2019) Influence of the Heat Dissipation Mode of Long-Flute Cutting Tools on Temperature Distribution during HFCVD Diamond Films. Crystals, 9, 394.
https://doi.org/10.3390/cryst9080394
|
[20]
|
Lei, C.-Q., Zhong, B., Zhang, Y., Zhang, J., Wang, S. and Shu, H.-B. (2010) Glycogen Synthase Kinase 3β Regulates IRF3 Transcription Factor-Mediated Antiviral Response via Activation of the Kinase TBK1. Immunity, 33, 878-889.
https://doi.org/10.1016/j.immuni.2010.11.021
|
[21]
|
Zhao, P., Wong, K.I., Sun, X., Reilly, S.M., Uhm, M., Liao, Z., et al. (2018) TBK1 at the Crossroads of Inflammation and Energy Homeostasis in Adipose Tissue. Cell, 172, 731-43.e12. https://doi.org/10.1016/j.cell.2018.01.007
|
[22]
|
Lama, L., Adura, C., Xie, W., Tomita, D., Kamei, T., Kuryavyi, V., et al. (2019) Development of Human cGAS-Specific Small-Molecule Inhibitors for Repression of dsDNA-Triggered Interferon Expression. Nature Communications, 10, 2261. https://doi.org/10.1038/s41467-019-08620-4
|
[23]
|
Bai, L.-Y., Chiu, C.-F., Kapuriya, N.P., Shieh, T.-M., Tsai, Y.-C., Wu, C.-Y., et al. (2015) BX795, a TBK1 Inhibitor, Exhibits Antitumor Activity in Human Oral Squamous Cell Carcinoma through Apoptosis Induction and Mitotic Phase Arrest. European Journal of Pharmacology, 769, 287-296. https://doi.org/10.1016/j.ejphar.2015.11.032
|
[24]
|
Chen, W., Luo, K., Ke, Z., Kuai, B., He, S., Jiang, W., et al. (2017) TBK1 Promote Bladder Cancer Cell Proliferation and Migration via Akt Signaling. Journal of Cancer, 8, 1892-1899. https://doi.org/10.7150/jca.17638
|
[25]
|
Choi, E.A., Choi, Y.-S., Lee, E.J., Singh, S.R., Kim, S.C. and Chang, S. (2019) A Pharmacogenomic Analysis Using L1000CDS2 Identifies BX-795 as a Potential Anticancer Drug for Primary Pancreatic Ductal Adenocarcinoma Cells. Cancer Letters, 465, 82-93. https://doi.org/10.1016/j.canlet.2019.08.002
|
[26]
|
Clark, K., Peggie, M., Plater, L., Sorcek, R.J., Young, E.R.R., Madwed, J.B., et al. (2011) Novel Cross-Talk within the IKK Family Controls Innate Immunity. Biochemical Journal, 434, 93-104. https://doi.org/10.1042/BJ20101701
|
[27]
|
Pardanani, A., Lasho, T., Smith, G., Burns, C.J., Fantino, E. and Tefferi, A. (2009) CYT387, a Selective JAK1/JAK2 Inhibitor: In Vitro Assessment of Kinase Selectivity and Preclinical Studies Using Cell Lines and Primary Cells from Polycythemia Vera Patients. Leukemia, 23, 1441-1445. https://doi.org/10.1038/leu.2009.50
|
[28]
|
Ng, A.H.S. (2018) Nationalism and the Intangible Effects of Violence in Malik Sajad’s Munnu: A Boy from Kashmir. South Asian Review, 39, 159-174. https://doi.org/10.1080/02759527.2018.1515803
|
[29]
|
Thomson, D.W., Poeckel, D., Zinn, N., Rau, C., Strohmer, K., Wagner, A.J., et al. (2019) Discovery of GSK8612, a Highly Selective and Potent TBK1 Inhibitor. ACS Medicinal Chemistry Letters, 10, 780-785.
https://doi.org/10.1021/acsmedchemlett.9b00027
|
[30]
|
Beyett, T.S., Gan, X., Reilly, S.M., Chang, L., Gomez, A.V., Saltiel, A.R., et al. (2018) Carboxylic Acid Derivatives of Amlexanox Display Enhanced Potency toward TBK1 and IKK ɛ and Reveal Mechanisms for Selective Inhibition. Molecular Pharmacology, 94, 1210-1219. https://doi.org/10.1124/mol.118.112185
|
[31]
|
Zhou, Z., Qi, J., Zhao, J., Lim, C.W., Kim, J.-W. and Kim, B. (2020) Dual TBK1/IKKɛ Inhibitor Amlexanox Attenuates the Severity of Hepatotoxin-Induced Liver Fibrosis and Biliary Fibrosis in Mice. Journal of Cellular and Molecular Medicine, 24, 1383-1398. https://doi.org/10.1111/jcmm.14817
|
[32]
|
Maniaci, C. and Ciulli, A. (2019) Bifunctional Chemical Probes Inducing Protein-Protein Interactions. Current Opinion in Chemical Biology, 52, 145-156. https://doi.org/10.1016/j.cbpa.2019.07.003
|
[33]
|
Crew, A.P., Raina, K., Dong, H., Qian, Y., Wang, J., Vigil, D., et al. (2018) Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1. Journal of Medicinal Chemistry, 61, 583-598. https://doi.org/10.1021/acs.jmedchem.7b00635
|
[34]
|
Johannes, J.W., Chuaqui, C., Cowen, S., Devereaux, E., Gingipalli, L., Molina, A., et al. (2014) Discovery of 6-aryl-azabenzimidaoles That Inhibit the TBK1/IKK-ε Kinases. Bioorganic & Medicinal Chemistry Letters, 24, 1138-1143. https://doi.org/10.1016/j.bmcl.2013.12.123
|
[35]
|
Wang, T., Block, M.A., Cowen, S., Davies, A.M., Devereaux, E., Gingipalli, L., et al. (2012) Discovery of Azabenzimidazole Derivatives as Potent, Selective Inhibitors of TBK1/IKK Kinases. Bioorganic and Medicinal Chemistry Letters, 22, 2063-2069. https://doi.org/10.1016/j.bmcl.2012.01.018
|
[36]
|
Vu, H.L. and Aplin, A.E. (2014) Targeting TBK1 Inhibits Migration and Resistance to MEK Inhibitors in Mutant NRAS Melanoma. Molecular Cancer Research, 12, 1509-1519. https://doi.org/10.1158/1541-7786.MCR-14-0204
|
[37]
|
Hasan, M., Dobbs, N., Khan, S., White, M.A., Wakeland, E.K., Li, Q.-Z., et al. (2015) Cutting Edge: Inhibiting TBK1 by Compound II Ameliorates Autoimmune Disease in Mice. The Journal of Immunology, 195, 4573-4577.
https://doi.org/10.4049/jimmunol.1500162
|